Investor Relations (IR) Questions: Optimer Pharmaceuticals OPTR
Click here to return to the biotech IRQ Index
Answers received: February 2013
The following are notes taken from my telephone conversation today (02/11/2013) with David Walsey, the VP of Investor Relations & Corporate Communications at Optimer.
1) When is the last time OPTR raised cash through an offering (diluted)?
Feb 2011: Offering included 6.9 million shares. The offering price was $11.25 and the company generated $77.6 million in proceeds.
2) How much cash (not cash equivalents) does OPTR have?
In Sept 2012 Optimer reported $98.2 million in cash, equivalents and short term investments. Since that time the following has occurred:
a) The company reported preliminary 4th quarter revenue from DIFICID alone of $21.3 million.
b) The company sold a subsidiary for $60 million.
Optimer will update investors when it reports 4th quarter results on February 28, 2013.
3) What and approximately when is the next known catalyst?
Right now the market is focused on the growth trajectory of revenue from DIFICID and the next update will be on February 28, 2013.
The company also has an ongoing Phase 3b Multi-Center, Double-Blind, Randomized, Placebo Controlled Study to Demonstrate the Safety and Efficacy of Fidaxomicin for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation,
For those of us that aren't doctors (like me) that means the prevention of CDAD in patients undergoing bone marrow transplants.
The ultimate goal of the ongoing trial is to expand DIFICID's label. The company plans an interim look during the 2nd half of 2013.
4) What is OPTR's quarterly cash burn?
Optimer does not give guidance on cash burn. However, it's President projected that the company would reach an operational breakeven point 3 years after the launch of DIFICID, giving Optimer a breakeven commitment of July 2014.
5) Does OPTR have an existing line of credit and if so how much can they draw against it?
Optimer does not have a line of credit.
The following are notes taken from my telephone conversation today (02/11/2013) with David Walsey, the VP of Investor Relations & Corporate Communications at Optimer.
1) When is the last time OPTR raised cash through an offering (diluted)?
Feb 2011: Offering included 6.9 million shares. The offering price was $11.25 and the company generated $77.6 million in proceeds.
2) How much cash (not cash equivalents) does OPTR have?
In Sept 2012 Optimer reported $98.2 million in cash, equivalents and short term investments. Since that time the following has occurred:
a) The company reported preliminary 4th quarter revenue from DIFICID alone of $21.3 million.
b) The company sold a subsidiary for $60 million.
Optimer will update investors when it reports 4th quarter results on February 28, 2013.
3) What and approximately when is the next known catalyst?
Right now the market is focused on the growth trajectory of revenue from DIFICID and the next update will be on February 28, 2013.
The company also has an ongoing Phase 3b Multi-Center, Double-Blind, Randomized, Placebo Controlled Study to Demonstrate the Safety and Efficacy of Fidaxomicin for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation,
For those of us that aren't doctors (like me) that means the prevention of CDAD in patients undergoing bone marrow transplants.
The ultimate goal of the ongoing trial is to expand DIFICID's label. The company plans an interim look during the 2nd half of 2013.
4) What is OPTR's quarterly cash burn?
Optimer does not give guidance on cash burn. However, it's President projected that the company would reach an operational breakeven point 3 years after the launch of DIFICID, giving Optimer a breakeven commitment of July 2014.
5) Does OPTR have an existing line of credit and if so how much can they draw against it?
Optimer does not have a line of credit.